

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
 Company AstraZeneca UK (acalabrutinib) Patient/carer groups African Caribbean Leukaemia Trust Anthony Nolan Black Health Agency for Equality Blood Cancer UK Cancer 52 Cancer Black Care Chronic Lymphocytic Leukaemia Support Association Helen Rollason Cancer Charity Independent Cancer Patients Voice Kevin Kararwa Leukaemia Trust Leukaemia Cancer Society Leukaemia Care Leukaemia UK Lymphoma Action Macmillan Cancer Support Maggie's Centres 	 All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Hospital Information Services – Jehovah's Witnesses Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee Scottish Medicines Consortium Welsh Government
Marie CurieSouth Asian Health Foundation	Comparator companies
Specialised Healthcare Alliance	AbbVie (venetoclax)
Tenovus Cancer Care	Accord (bendamustine, fludarabine)
WMUK	Aspen (chlorambucil)
	Baxter Healthcare (cyclophosphamide)
Healthcare professional groups	BeOne Medicines UK (zanubrutinib)
Association of Anaesthetists	Celltrion Healthcare UK (rituximab)
Association of Cancer Physicians	Dr Reddy's Laboratories
Association of Surgeons of Great	(bendamustine)
Britain and Ireland	Gilead Sciences (idelalisib)
British Blood Transfusion Society	Johnson & Johnson Innovative
British Geriatrics Society	Medicine (ibrutinib)
British Institute of Radiology	Pfizer (rituximab) Pocho (objectuzimab rituximab)
	Roche (obinutuzumab, rituximab)

Final stakeholder list for the evaluation of acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Oncology Pharmacy Association British Psychosocial Oncology Society British Society for Haematology British Society of Blood and Marrow Transplantation and Cellular Therapy British Society of Interventional Radiology British Transplantation Society Cancer Research UK NHS Blood and Transplant Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK CLL forum UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	 Sandoz (cyclophosphamide, rituximab) Sanofi (fludarabine) Seacross Pharmaceuticals (bendamustine) Zentiva (bendamustine) Relevant research groups Cochrane Haematological Group Genomics England Institute of Cancer Research Leukaemia Busters Lymphoma Research Trust MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient

Final stakeholder list for the evaluation of acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232] Issue date: July 2025



organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.